Malignancies in the PsABio population distinguished by time period since treatment initiation (safety set)
| UST | TNFi | |||||
| 0–6 months (n=457) | 7–12 months (n=467) | >12 months* (n=494) | 0–6 months (n=489) | 7–12 months (n=502) | >12 months* (n=557) | |
| n (%) | 3 (0.6) | 2 (0.4) | 3 (0.6) | 2 (0.4) | 3 (0.6) | 4 (0.7) |
| Events | Cutaneous T-cell lymphoma Parathyroid tumour Bowen’s disease | Lung neoplasm Meningioma | Colon cancer Malignant neoplasm of eye Prostate cancer | Lung adenocarcinoma Myelodysplastic syndrome | Renal oncocytoma Basal cell carcinoma Squamous cell carcinoma | Bladder neoplasm Colon cancer Malignant urinary tract neoplasm Squamous cell carcinoma |
The total number of patients is higher than the number in the full analysis set because the same patients were included several times for adverse event evaluation if they were switchers.
*Usually only malignancies diagnosed after a lag time of 12 months are attributable to a newly initiated treatment.
TNFi, tumour necrosis factor inhibitor; UST, ustekinumab.